Why the study?
No randomized trial had evaluated whether SGLT2 inhibitors reduce AF recurrence after catheter ablation in patients without established indications.
Does dapagliflozin reduce AF burden at 3 months after ablation in patients with persistent AF without established indications for SGLT2 inhibitors?
Population
200 patients with persistent AF undergoing first catheter ablation without established indications for dapagliflozin
Comparison
Dapagliflozin (10 mg once daily for 3 months) vs control
Design
Prospective, open-label, parallel-assignment randomized controlled trial
Follow-up
3 months
Key result
Dapagliflozin (10 mg daily for 3 months) did not significantly reduce atrial fibrillation burden compared to control after catheter ablation in patients with persistent AF (7.5% vs 8.1%; P=0.48).
Authors
Loading...
Dapagliflozin does not reduce AF burden after ablation; confirms no short-term benefit in persistent AF without SGLT2i indications.
RCT (n=200)
Open-label
1:1
Does dapagliflozin reduce AF burden at 3 months after ablation in patients with persistent AF without established indications for SGLT2 inhibitors?
Absolute Event Rate: 7.5% vs 8.1%
p-value: p=0.48
A 3-month course of dapagliflozin did not significantly reduce AF burden or early arrhythmia recurrence after first catheter ablation in patients with persistent AF without other indications for SGLT2 inhibitors.
Jiang et al. (2025) conducted an RCT in Persistent atrial fibrillation (n=200). Dapagliflozin vs. Control was evaluated on Atrial fibrillation burden at 3 months after ablation (p=0.48). Dapagliflozin (10 mg daily for 3 months) did not significantly reduce atrial fibrillation burden compared to control after catheter ablation in patients with persistent AF (7.5% vs 8.1%; P=0.48).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: